Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Dec;9(12):e838-e847.
doi: 10.1016/S2352-3018(22)00266-1.

Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised controlled trial

Affiliations
Randomized Controlled Trial

Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised controlled trial

Alison J Rodger et al. Lancet HIV. 2022 Dec.

Abstract

Background: High levels of HIV testing in men who have sex with men remain key to reducing the incidence of HIV. We aimed to assess whether the offer of a single, free HIV self-testing kit led to increased HIV diagnoses with linkage to care.

Methods: SELPHI was an internet-based, open-label, randomised controlled trial that recruited participants via sexual and social networking sites. Eligibility criteria included being a man or trans woman (although trans women are reported separately); being resident in England or Wales, UK; being aged 16 years or older; having had anal intercourse with a man; not having a positive HIV diagnosis; and being willing to provide name, email address, date of birth, and consent to link to national HIV databases. Participants were randomly allocated (3:2) by computer-generated number sequence to receive a free HIV self-test kit (BT group) or to not receive this free kit (nBT group). Online surveys collected data at baseline, 2 weeks after enrolment (BT group only), 3 months after enrolment, and at the end of the study. The primary outcome was confirmed (linked to care) new HIV diagnosis within 3 months of enrolment, analysed by intention to treat. Those assessing the primary outcome were masked to allocation. This study is registered with the ISRCTN Clinical Trials Register, number ISRCTN20312003.

Findings: 10 111 participants (6049 in BT group and 4062 in nBT group) enrolled between Feb 16, 2017, and March 1, 2018. The median age of participants was 33 years (IQR 26-44 years); 9000 (89%) participants were White; 8118 (80%) participants were born in the UK; 81 (1%) participants were transgender men; 4706 (47%) participants were university educated; 1537 (15%) participants had never been tested for HIV; and 389 (4%) participants were taking pre-exposure prophylaxis. At enrolment, 7282 (72%) participants reported condomless anal sex with at least one male partner in the previous 3 months. In the BT group, of the 4511 participants for whom HIV testing information was available, 4263 (95%) reported having used the free HIV self-test kit within 3 months.Within 3 months of enrolment there were 19 confirmed new HIV diagnoses (0·31%) in 6049 participants in the BT group and 15 (0·37%) of 4062 in the nBT group (p=0·64).

Interpretation: The offer of a single, free HIV self-test did not lead to increased rates of new HIV diagnoses, which could reflect decreasing HIV incidence rates in the UK. Nonetheless, the offer of a free HIV self-testing kit resulted in high HIV testing rates, indicating that self-testing is an attractive testing option for a large group of men who have sex with men.

Funding: UK National Institute for Health and Care Research.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MB has received speaker's fees from Gilead and Bristol Myers Squibb. FB and TCW have received consultancy fees from Gilead. All other authors declare no competing interests.

Figures

Figure 1
Figure 1. Trial flow diagram for the first stage of randomisation
Excluded participants could only be included in one ineligibility category or be categorised as having been randomly assigned in error. Due to the nature of the ascertainment of the primary outcome (linkage with national databases), all randomly assigned participants are included in the analysis of the primary outcome. Participants who had been randomised in error, who were transgender women, or who asked for complete data removal were excluded from this analysis.
Figure 2
Figure 2. Kaplan-Meier plot of time, in months, until confirmed diagnosis of HIV for participants in the BT group and those in the nBT group
The vertical dashed line at 3 months shows when the primary endpoint was analysed.

Comment in

References

    1. Girometri N, Delpech V, McCormack S, et al. The success of HIV combination prevention: the Dean street model. HIV Med. 2021;22:892–97. - PubMed
    1. Public Health England. Trends in HIV testing, new diagnoses and people receiving HIV-related care in the United Kingdom: data to the end of December 2019. 2020. [accessed May 10, 2022]. https://assets.publishing.service.gov.uk/government/uploads/system/uploa... .
    1. O’Halloran C, Sun S, Nash S, et al. HIV in the United Kingdom: towards zero 2030. 2019. [accessed May 10, 2022]. https://assets.publishing.service.gov.uk/government/uploads/system/uploa... .
    1. Brown AE, Nash S, Connor N, et al. Towards elimination of HIV transmission, AIDS and HIV-related deaths in the UK. HIV Med. 2018;20:74–76. - PubMed
    1. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53–60. - PMC - PubMed

Publication types

Associated data